Probucol reduces plasma lipid peroxides in man.
Although primarily used as a lipid lowering drug, probucol also possesses anti-oxidant activity and has been shown in animal models to inhibit or delay the progression of atherosclerosis. It has been suggested that this anti-atherosclerotic effect may occur through inhibition of free radical oxidation of low density lipoprotein. The aim of this study was to investigate the effects of probucol on free radical activity in hyperlipidaemic patients. Plasma lipid peroxides were measured before probucol treatment, at 4 and 12 weeks treatment and then 4 weeks after stopping probucol. Lipid peroxide concentrations were significantly reduced during and 4 weeks after stopping treatment with probucol, when compared with baseline values. There were no changes in plasma vitamin E concentrations. The results of this study indicate that probucol reduces lipid peroxidation in patients, an effect which may occur through a free radical scavenging action.
Paterson
J R
JR
Institute of Biochemistry, Royal Infirmary, Glasgow, UK.
Rumley
A G
AG
Oldroyd
K G
KG
Tait
G W
GW
Smellie
W S
WS
Packard
C J
CJ
Shepherd
J
J
Lorimer
A R
AR
D000328:Adult; D002784:Cholesterol / Q000097:blood; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D008054:Lipid Peroxides / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011341:Probucol / Q000627:therapeutic use*; D014810:Vitamin E / Q000097:blood
D008054:Lipid Peroxides; D014810:Vitamin E; D002784:Cholesterol; D011341:Probucol